Document is current
Any future updates will be listed below
-
Authors
Dobrosavljevic, Maja http://orcid.org/0000-0002-3887-9669
Kuja-Halkola, Ralf
Li, Lin
Chang, Zheng
Larsson, Henrik
Du Rietz, Ebba
-
Funding
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (754285)
Vetenskapsrådet (2018-02599)
Hjärnfonden (FO2021-0115)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2019-00176)
Svenska Sällskapet för Medicinsk Forskning (PD20-0036)
Fredrik och Ingrid Thurings Stiftelse (2021-00638)
Fonden för Psykisk Hälsa
The Strategic Research Area in Epidemiology and Biostatistics (SFOepi).
Örebro University
- License Information
-
More Information
Article History
Received: 11 May 2023
Accepted: 13 November 2023
First Online: 22 November 2023
Declarations
:
: This project was reviewed and approved by the Regional Ethics Committee at the Karolinska Institutet, Stockholm, Sweden (2010/322-31/2). All participants provided informed consent.
: Not applicable.
: HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals, and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. EDR has served as a consultant for Shire Sweden AB (fully owned subsidiary of Takeda Pharmaceutical Company Limited) outside the submitted work. Other authors have no competing interests.
